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Abstract
Background: Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile
dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in
juvenile dermatomyositis as an adjunctive treatment.
Methods: Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months
of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS),
Manual Muscle Testing (MMT8) and physician’s global assessment (PGA) were recorded. Skin disease was assessed
using the modified skin disease activity score (DAS). Data were analysed using Friedman’s test for repeated
measures analysis of variance.
Results: Compared to baseline, there were improvements at 6 and 12months in skin disease (χ2(2) = 15.52, p = 0.00043),
global disease (χ2(2) = 8.14, p = 0.017) and muscle disease (CMAS χ2(2) = 17.02, p = 0.0002 and MMT χ2(2) = 10.56, p = 0.005)
in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global
disease activity (χ2(2) = 6.73, p = 0.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median
initial prednisolone dose was 6 [0–10] mg, and final was 2.5 [0–7.5] mg (p< 0.0001). Fifty-four per cent of patients had a
reduction in the number and/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from
infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6%
due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered
serious.
Conclusion: Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab
and adalimumab.
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Background
Juvenile dermatomyositis (JDM) is a rare inflammatory
disease of childhood that predominantly affects muscles
and skin but is also a systemic multi-organ disease [1]. It
is the most common idiopathic inflammatory myopathy
(IIM) of childhood: incidence of 2–3 new cases per mil-
lion/children/year [2]. The treatment of JDM has been
challenging. The reasons include the rarity of the dis-
ease, its heterogeneous clinical phenotype and the small
number of randomized, double-blind controlled clinical
trials. Traditional treatment includes glucocorticoids and
conventional immunosuppressive or immunomodulatory
agents [3]. As treatment of refractory disease has been
difficult, there is growing interest in evaluating novel
therapies including newer biologics that target various
pathways implicated in the pathogenesis of myositis [4]..
Anti-TNF biologics have been successful in treating
various chronic inflammatory disorders [5, 6]. TNF has
been identified in high levels in JDM patients who have
a long disease course and calcinosis, which can be a de-
bilitating complication [7–9]. There is some evidence
that prolonged active disease is related to this complica-
tion and that its incidence can be reduced by earlier dis-
ease control [10]. A previous case series of 5 patients
with refractory JDM treated with infliximab showed im-
provement in all 5 cases in core set measures [11].
Therefore, TNF may be a good potential therapeutic tar-
get for the treatment of JDM: however, evidence for effi-
cacy of TNF blockade is limited. The goal of this study
was to describe the efficacy and safety of anti-TNF treat-




Data from JDM patients treated with anti-TNF agents
were analysed from the JDCBS [2]. Informed written
parental consent and age-appropriate assent were ob-
tained. This research was approved by the UK Northern
& Yorkshire Medical Research and Ethics Committee.
All patients had a diagnosis of definite or probable JDM
according to the Bohan and Peter criteria [12, 13]. The
new classification criteria were not employed as they are
not yet used in routine clinical practice. Patients were
included in the analysis if they had ever received anti-
TNF therapy lasting for at least 3 months. Patients were
excluded from the analysis if they were treated with eta-
nercept or had no recorded outcome variables or dates
of starting or ending anti-TNF. Indications for starting
anti-TNF were active skin disease, calcinosis, muscle dis-
ease or general disease activity that the clinician consid-
ered to be refractory to conventional treatment.
Sixty patients treated with anti-TNF were identified,
and data on the demographics, concomitant disease-
modifying anti-rheumatic drugs (DMARDs) and adverse
events are presented for this combined cohort in order
to analyse treatments targeting this mechanism as a
whole. Patients were excluded from subsequent efficacy
analyses if they had allergic reactions to the first infusion
and did not receive another anti-TNF (n = 2). For effi-
cacy analysis, patients treated with infliximab alone (6
mg/kg every 4 weeks; n = 39) and patients treated with
infliximab (6 mg/kg every 4 weeks) then adalimumab
(24 mg/m2 every other week; n = 15) were analysed as
two separate groups. Changes in levels of disease activity
at 6 and 12 months after infliximab and adalimumab
start were analysed for the respective groups. Finally, pa-
tients treated with adalimumab alone (24 mg/m2 every
other week; n = 4) were not analysed statistically due to
low numbers, but their clinical scores are described. A
flow diagram outlining which patients were included in
each analysis is presented Figure S1 in Supplementary
Methods. Although patients who received etanercept
were excluded from analysis, a description of their clin-
ical scores is presented in Supplementary Results.
Data collection
Patient clinical data at 0, 6 and 12months after inflixi-
mab/adalimumab start are described. For the safety ana-
lysis, patient clinical data were collected until the
present date. Core outcome variables for JDM were col-
lected including the Childhood Myositis Assessment
Scale (CMAS, score range 0–53, with high scores indi-
cating minimal disease) [14] and Manual Muscle Testing
of 8 groups (MMT8, score range 0–80, with high scores
indicating minimal disease) [15] that exist to standardize
the muscle assessment. Both are part of the JDM Paedi-
atric Rheumatology International Trials Organisation
(PRINTO) [16] and International Myositis Assessment
and Clinical Studies Group (IMACS) [17] core disease
activity measures. The physician’s global assessment of
disease activity (PGA, score range 0–10, with low scores
indicating minimal disease) and the modified Disease
Activity Score as a measure of skin disease activity
(DAS, score range 0–5, with low scores indicating min-
imal disease) [18] were collected. Modified DAS includes
the 4 skin components of a simplified version of the ori-
ginal DAS tool, which are Gottron’s papules (1 point),
heliotrope rash (1 point), vasculitis (1 point) and
erythema (2 points). The presence of calcinosis was also
recorded based on a combination of physician’s assess-
ment and imaging such as X-rays. As objective measures
of calcinosis were not collected for this cohort, analyses
of whether calcinosis improved were based on the physi-
cian’s assessment at the date of visit, which may have in-
corporated X-rays. Inter-observer variation was not
recorded. Data on other medications received prior to
the start, at start and at 12 months of anti-TNF therapy
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were recorded, including the dose of steroid treatment.
Adverse events that occurred from the start of anti-TNF
treatment until the end of follow-up were recorded. Se-
vere adverse reactions were defined as the occurrence of
death, hospitalization or any event that caused perman-
ent damage. For patients who switched between anti-
TNF therapies (infliximab to adalimumab), the reason
for the switch and the duration of prior infliximab treat-
ment at the time of the switch were noted.
Statistical analysis
The non-parametric Friedman’s test for repeated mea-
sures analysis of variance (ANOVA) was performed to
identify significant main effects of time on clinical mea-
sures of disease activity. Separate analyses were per-
formed for patients who received infliximab alone and
for patients who received infliximab and then adalimu-
mab. In the latter analysis, the date of switch from inflix-
imab to adalimumab was taken as a new treatment start
time. Post hoc tests to identify time-points at which clin-
ical scores differed significantly from each other were
performed using Wilcoxon signed-rank tests. The
Bonferroni correction was used to adjust for multiple
hypothesis testing, such that p values below 0.017 were
considered statistically significant in the post hoc tests.
Steroid doses at the start and 12 months after the start
of anti-TNF therapy were compared using the Wilcoxon
signed-rank test. Statistical analysis was performed using
R version 3.5.1 and plots were generated using Graphpad
Prism 5.
Results
Patient demographics, clinical features and medication
Of 60 patients assessed, 72% were female and 77% were
Caucasian (Table 1). Most had been diagnosed with def-
inite JDM (87%), with a minority diagnosed with prob-
able JDM (3%), JDM overlap with scleroderma (7%) or
JDM overlap with chronic arthritis (2%) The median age
at disease onset was 5.2 [3.3–9.7] years. Median disease
duration at the beginning of anti-TNF treatment was 3.1
[1.7–4.9] years, and median duration on anti-TNF ther-
apy was of 2.5 [1.5–4] years. Of these patients, 59 had an
autoantibody result: 19 (32%) had anti-TIF1γ, 7 (12%)
had anti-NXP2, 1 (2%) had anti-MDA5, 1 (2%) had anti-
Mi2, 1 (2%) had anti-SRP, 1 (2%) had anti-PL-7 and 1
(2%) had anti-HMGCR myositis-specific autoantibodies.
A further 2 (3%) had anti-PMScl, and 1 (2%) had anti-
Topo myositis-associated autoantibodies. One patient
(2%) had both anti-U1RNP and anti-TIF1γ autoanti-
bodies, 13 (22%) had unidentified autoantibodies and 11
(19%) had no-detectable autoantibodies.
Regarding prior treatment, 98% of the patients were
on methotrexate, azathioprine or hydroxychloroquine in
monotherapy or in combination before starting anti-
TNF (Table 2). Steroids were given prior to anti-TNF
treatment in 92% of patients; of those with available
data, 68% were still on steroids at anti-TNF start consist-
ent with recalcitrant disease. Intravenous immunoglobu-
lin (IVIg) treatment had been received by 11% of the
patients prior to anti-TNF treatment, whilst 13% were
still on IVIg at the start of the anti-TNF treatment.
43% of the patients had finished treatment with cyclo-
phosphamide (typically 6–7 doses, administered intra-
venously) before receiving anti-TNF. Five per cent (n =
3) of the patients started anti-TNF whilst they were still
on cyclophosphamide (2 patients started anti-TNF 2 to
3 weeks before finishing the last cyclophosphamide dose
of the course, and only 1 patient started anti-TNF before
cyclophosphamide). After 12 months of anti-TNF ther-
apy, none were still on cyclophosphamide. The median
prednisolone daily dose at anti-TNF start was 6 [0–10]
mg, and after 12 months of anti-TNF treatment was 2.5
Table 1 Demographic and serological features of patients who
received anti-TNF therapy (n = 60)








Definite JDM 52 (87%)
Probable JDM 2 (3%)
JDM overlap with scleroderma 4 (7%)
JDM overlap with chronic arthritis 1 (2%)
Age at disease onset 5.2 [3.3–9.7]
Disease duration at anti-TNF start 3.1 [1.7–4.9]











Anti-U1RNP and anti-TIF1γ 1 (2%)
Unidentified autoantibodies 13 (22%)
No-detectable autoantibodies 11 (19%)
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[0–7.5] mg (p < 0.0001; Fig. 1, complete data available on
43 patients).
Efficacy on infliximab therapy
In the 39 patients that received infliximab alone, global
disease activity improved (χ2(2) = 8.14, p = 0.017; Fig. 2a).
PGA decreased from 3.2 [1.8–5] at anti-TNF initiation
to 0.9 [0.5–2.4] (p = 0.005) at 6 months and to 0.5 [0.3–
1.3] at (p = 0.0003) 12 months. Skin involvement im-
proved (χ2(2) = 15.52, p = 0.00043; Fig. 2b). Modified
DAS decreased from 4 [1.5–5] at anti-TNF initiation to
2 [0–4] at 6 months (p = 0.002) and to 1 [0–3.3] at 12
months (p = 0.0006). Muscle involvement also improved
in terms of CMAS and MMT 80 (χ2(2) = 17.02, p =
0.0002—Fig. 2c and χ2(2) = 10.56, p = 0.005—Fig. 2d, re-
spectively). Median CMAS increased from 42 [37.8–49]
at anti-TNF initiation to 50 [47–53] at 6 months (p =
0.03; not considered statistically significant following
Bonferroni correction) and to 52 [50–53] (p = 0.0008) at
12 months. Median MMT 80 increased from 72 [59.8–
78.3] to 77 [73–80] at 6 months (0.02; not significant)
and to 80 [78–80] at 12 months (0.003).
Of the 39 patients treated with infliximab alone, 15 pa-
tients were identified who had been treated with cyclo-
phosphamide 1.9 [0.8–2.2] years prior to starting
infliximab. Indications for cyclophosphamide include se-
vere skin disease, severe muscle weakness, severe calci-
nosis, widespread vasculitis and failure to respond to
first-line treatment. When these patients were excluded
and the remaining patients analysed (n = 24), improve-
ments in disease activity were observed in the remaining
patients treated with infliximab alone (n = 24) for skin
disease activity (χ2(2) = 6.08, p = 0.048 for modified DAS)
and muscle disease activity (χ2(2) = 10.17, p = 0.006 for
CMAS). Modified DAS reduced from 4 [1–4.3] at inflixi-
mab start to 2 [0–3] at 6 months (p = 0.018, not consid-
ered significant following Bonferroni correction) and 1
[0–3] at 12 months (p = 0.013). CMAS increased from 44
[38.8–50.5] at anti-TNF start to 52.5 [50–53] at 6
months (p = 0.11) and 52 [50–53] at 12 months (p =
0.03, not significant).
Efficacy after switching to adalimumab
Fifteen patients (25%) switched their anti-TNF treatment
from infliximab to adalimumab. The median time of
switching from infliximab to adalimumab was 2.3
months [1–3.8]. Ten (66.7%) of the switches were due to
treatment inefficacy, 1 (6.6%) related to patient prefer-
ence for subcutaneous administration and 4 (26.7%)
were due to adverse events such as hypersensitivity reac-
tions. From those 10 patients that switched due to treat-
ment inefficacy, 8 were mainly due to active skin disease
(5 had calcinosis lesions progressing). Only 3 of those 10
switches happened before 1 year on infliximab; all the
others happened after 2 to 3 years on the drug.
For the patients who switched from infliximab to ada-
limumab (n = 15 patients), there was improvement in
global disease activity (χ2(2) = 6.73, p = 0.03; Fig. 3a).
PGA decreased from 1.2 [1–2.7] at adalimumab initi-
ation to 0.5 [0.1–1.4] (p = 0.017; borderline significant)
at 12 months. There were trends towards improvement
in Modified DAS, CMAS and MMT8 (Fig. 3b–d).
For the limited number of patients on adalimumab
alone (n = 4), median physician’s VAS at anti-TNF start
Table 2 Treatment at time of the first assessment of the 60 patients identified
Treatment Previously At start of anti-TNF After 12 months on anti-TNF
MTX/AZA/HQL1 48 (98%), n = 49 43 (80%), n = 56 41 (89%), n = 46
Cyclophosphamide 26 (43%), n = 60 3 (5%), n = 60 0, n = 43
Immunoglobulin 5 (11%), n = 47 6 (13%), n = 46 1 (2.5%), n = 40
Oral steroids 47 (92%), n = 51 26 (68%), n = 38 26 (58%), n = 45
2 or more DMARDs 48 (98%), n = 49 30 (64%), n = 47
MTX methotrexate, AZA azathioprine, HQL hydroxychloroquine, n (%) absolute numbers (percentages) from the number of patients with available data
1Mycophenylate mofetil (MMF) was not used in the patients in this study
Fig. 1 Steroid-sparing effect of use of anti-TNF therapy. Dose of
prednisolone (mg/day) at anti-TNF start and 12 months of anti-TNF
treatment. n = 43 patients (number of patients with complete
data available)
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was 2.6 (IQR 1.8–3.4), was 1.0 (IQR 0.5–1.25) at 6
months after anti-TNF start and was 1.5 (IQR 1.38–1.8)
at 12 months after anti-TNF start. Median Modified
DAS at anti-TNF start was 2 (IQR 1.5–2.3), was 3 (IQR
1.5–4) at 6 months after anti-TNF start and was 1 (IQR
0–2.5) at 12 months after anti-TNF start. Median CMAS
at anti-TNF start was 52 (IQR 45–52), and there was no
change over the year.
Resolution of calcinosis
Within the cohort of 60 patients, 28 patients (47%) with
calcinosis were identified during their disease course up
to the time of analysis. From the data recorded within
the JDCBS [2] dataset, from the 28 patients, 15 (54%)
had a reduction in the number and/or size of calcinotic
lesions and calcinosis completely resolved in 8 (29%).
Three out the 28 patients had fewer than 3 lesions which
remained stable, and 3 out of the 28 patients had wide-
spread lesions which remained stable. In 7, there were
not sufficient data to evaluate changes. From the 15 pa-
tients that had a reduction in the number and/or size of
calcinotic changes, we then further sub-analysed the 11
cases in which we had access to more detailed clinical
information. This showed that the median time to
improve was 2.75 [0.9–4] years, with a minimum of
0.25 years (3 months) and a maximum of 10 years.
From those 11 patients, the calcinosis completely
resolved in 4 of them in a median time of 2.8 [0.73–
6.9] years and anti-TNF treatment was suspended in
3 of them with a median time of 4.6 [3–9] years after
the beginning of the drug.
Adverse events
A total of 29 adverse events were reported, of which 12
were severe adverse events: 9 were allergic reactions to
infliximab (HACA levels not routinely available in the
UK), and there were 3 hospital admissions of Infliximab
patients (sepsis in one and pneumonia in 2). One patient
died due to small bowel perforation (probably secondary
to disease damage) thought to be due to calcinosis in the
intestinal walls. The patient was on infliximab for 6 years
and then swapped to adalimumab for nearly 1 year be-
fore time of death. The remaining adverse reactions (n =
17) were not severe: 14 (82.4%) were due to infectious
Fig. 2 Clinical measures over time in patients treated with infliximab (total of 43 patients). Clinical outcome measures of patients on infliximab
are shown at baseline (time of starting infliximab) and at 6 and 12 months of infliximab treatment. a PGA, b Modified DAS, c CMAS and d MMT.
n, number of patients with available data; PGA, Physician Global Assessment; DAS, Disease Activity Score; CMAS, Childhood Myositis Assessment
Scale; MMT, Manual Muscle Testing
Campanilho-Marques et al. Arthritis Research & Therapy           (2020) 22:79 Page 5 of 9
causes (5 bacterial upper respiratory infections, 4 viral
infections, 2 skin infections, 2 episodes of tonsillitis, 1
episode of chicken-pox) and 3 (17.6%%) were due to
local injection site reaction (n = 2) and 1 episode of skin
rash. In 4 of the mild to moderate adverse reactions the
drug had to be discontinued (2 patients on adalimumab
had injection site reactions and 2 patients on infliximab
had recurrent skin infections) whilst in the remaining
patients temporarily withholding the drug proved suffi-
cient. No tuberculosis or malignancy was recorded. Ac-
cording to the exposure time, a total of 13.9 adverse
reactions occurred by 100 patient-years. 5.7 serious ad-
verse reactions by 100 patient-years were reported.
Discussion
Biologic drugs have been used off-label since 2000 for
JDM and other inflammatory myositis diseases with en-
couraging results [19]. High levels of TNF-α have been
reported in JDM patients with a long disease course sug-
gesting that it may play a significant role in refractory
disease [7]. A recent study published by Spencer et al.
[19], the results of a survey on CARRA members’ experi-
ence of using biologics in JDM, showed that survey
responders considered that use of biologics significantly
reduced complications in JDM (such as calcinosis,
muscle atrophy, lipodystrophy) and were a logical thera-
peutic step after failure of corticosteroid and other im-
munosuppressive therapy, in JDM patients with resistant
disease.
In our study, those who received infliximab and who
switched from infliximab to adalimumab showed im-
provement in terms of global disease and improvement
compared to their own baseline, but we cannot exclude
the effects of other concomitant medications due to the
lack of a control group. Muscle and skin disease ap-
peared to reduce with infliximab treatment, with im-
provement in CMAS and MMT8 and the modified DAS.
Importantly, we observed a reduction in steroid dose
after 12 months of treatment with anti-TNF, which may
suggest a possible steroid-sparing effect.
Major limitations of this study include missing data
(commonly encountered in multi-site cohort studies)
and the lack of a control group. We recognize that it is a
limitation of our study that controls were not able to be
included in the analysis. We have previously used obser-
vational data to model efficacy of cyclophosphamide,
Fig. 3 Clinical measures in patients who switched from infliximab to adalimumab (total of 16 patients). Score shown at 0 (time of switch), 6 and
12months of Adalimumab treatment. a PGA, b Modified DAS, c CMAS and d MMT. n, number of patients with available data; PGA, Physician
Global Assessment; DAS, Disease Activity Score; CMAS, Childhood Myositis Assessment Scale; MMT, Manual Muscle Testing
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another second-line treatment for JDM, using the MSM
method which allowed us to compare disease activity in
patients treated with the drug to those who were not
treated with the drug [20]. However, this method was
not feasible in this study because we included two differ-
ent drugs (infliximab and adalimumab) and treatment
durations were heterogeneous. Obtaining evidence for
second-line treatments in this rare disease is challenging,
and there is an important role for observational studies
and large case series like this study. Therefore, we can-
not exclude effects of concomitant medications etc.
Infliximab was switched to adalimumab in 15 patients
(25%). Ten (66.7%) of the switches were due to incom-
plete control of disease, mainly due to lack of skin dis-
ease control. The remaining causes for switching were
adverse effects and patient preference.
Calcinosis remains a significant source of morbidity
for many JDM patients, yet it is poorly understood and
lacks uniform treatment approaches compared to other
aspects of JDM. A recent study published by the CARRA
group [21] emphasizes the inconsistency in the pub-
lished literature regarding therapeutic effectiveness. The
authors suggest that this can be explained by the relative
inexperience of physicians and the multitude of different
treatments and treatment scenarios [21]. In our study,
there was a reduction in the number and/or size of calci-
notic lesions in 54% of the patients that were on inflixi-
mab/adalimumab and calcinosis completely resolved in
29% of them, although we cannot attribute these effects
to anti-TNF treatment alone. It was also noted that the
reduction in number and size of calcinosis needed nearly
2 years on anti-TNF treatment. Although we had a pa-
tient that showed evident reduction on calcinosis lesions
only after 3 months on anti-TNF treatment, the majority
needed a much longer time and in one case it was neces-
sary to continue 10 years of anti-TNF treatment until
the calcinosis completely resolved. This highlights that
an immediate improvement on the calcinosis should not
be expected, and the anti-TNF treatment should not be
stopped if an immediate improvement is not seen.
Regarding safety, the majority of the adverse events
were mild to moderate and mostly due to infections
causes. However, we had 12 serious adverse events,
mostly (n = 9) related with allergic reactions to inflixi-
mab. Administration of infliximab is associated with a
well-recognized risk of infusion-related adverse events.
The exact aetiology and pathogenesis of those infusion
reactions are often unclear, and findings regarding their
allergic/immune nature are inconsistent [22]. Overall the
anti-TNF drugs seemed to be well-tolerated in our
population with an incidence of 5.7 serious adverse reac-
tions by 100 patient-years, which is consistent with the
literature on adult patients [23]. Importantly, the major-
ity of patients had no adverse effects and tolerated the
infliximab/adalimumab well, and in the context of pa-
tients needing long-term treatment, this could be of
benefit.
This study is one of the largest to describe the use of
infliximab and adalimumab in a large national cohort of
JDM patients. Further clinical studies are required to as-
sess the efficacy of anti-TNF treatment in JDM, control-
ling for the effects of other DMARDS, and to ascertain
the optimum timing for treatment initiation and cessa-
tion. Stratified analysis by autoantibody subgroups could
be addressed in future studies with greater numbers.
Conclusions
Reductions in muscle and skin disease, including calci-
nosis, were seen following treatment with infliximab and
adalimumab. Infliximab and adalimumab were well-
tolerated and the majority of patients had no adverse
effects.
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